STITCHERADS
SticherAds, the social performance advertising platform for online retailers, today revealed it is one of a select few companies to complete the pilot Preferred Marketing Developer (PMD) Ads Incubator Program at Facebook® headquarters in Menlo Park, California.
Recently qualified as a PMD for Ads by Facebook, StitcherAds today also announces the launch of the newest edition of its Software as a Service (SaaS) platform, enabling online retailers to quickly put an ad for the right product in front of the right consumer at the right time and on the right device.
A brand new method of retargeting prospective buyers, StitcherAds’ new offering is a comprehensive yet affordable advertising suite allowing retailers to create more consistent and measurable returns on their Facebook advertising investments. In a major innovation for the industry, StitcherAds charges on a monthly subscription basis rather than percentage of ad spend model.
StitcherAds, previously known as Betapond, has consistently led in marketing innovation on the Facebook platform. Selected for ‘incubation’ by Facebook at its HQ, following a competitive selection process, the StitcherAds development team there refined its revolutionary method of analysing site behavioural data helping place the most attractive offers in front of the correct consumers. This allows retailers unparalleled prospecting and retargeting across desktop, tablet, and mobile.
Michael Randall, global director of Facebook’s preferred marketing developer program, said: “ StitcherAds' focus on online retailers is a great example of how our PMD partner ecosystem is becoming more diverse, to better support the vertical-specific needs of advertisers. StitcherAds' engineering culture has a lot in common with Facebook's own and we were delighted to work with them."
StitcherAds helps online retail marketers in three ways:-
Saves precious time
Facebook isn’t just about scale, despite having 1.2 Billion people. It also now enables powerful targeted reach for Direct Response advertisers. But it can be time consuming to use native tools like PowerEditor or other solutions not specifically designed for the needs of online retailers. Because StitcherAds is designed around the needs of online retail marketers – making it easy to create ads at scale from the feed of a product catalogue, for example – its features enable significant time savings. Allowing for more ad testing, more inventory changes and better sales.
More comprehensive retargeting
StitcherAds sees 70% of impressions and 65% of conversions now happening for its customers on tablet and mobile. But many retailers continue to use remarketing solutions that only reach people on desktop. StitcherAds makes it easy to prospect and retarget people with the right product across device and measure their response in near real time. Unlike other remarketing solutions, StitcherAds stops showing ads to consumers who have already bought the product, preventing wastage and potential brand damage.
Sophisticated Rules-based Optimisation
StitcherAds lets retailers create rules to automatically turn off ads falling below key performance criteria such as Cost Per Acquisition, or for products with limited stock. Equally, StitcherAds rewards the most effective ads providing insights for sharper retailer advertising – protecting their budget even while the marketer is sleeping.
A key benefit of this enhanced advertising armoury is that retailers such as outdoor flash sales specialist SportPursuit, can match the right buyer at the right time in their decision-making process to optimize the return on their social ad spend.
Anna Gardner, online marketing manager for SportPursuit, said: “ StitcherAds has reduced by more than 50% the amount of time it takes us to get campaigns live. This has allowed us to experiment further with campaigns targeting, the content of our ads and focus on strategy rather than manual workload."
Declan Kennedy, CEO and Co-Founder of StitcherAds said, “The savviest online retailers now realise that Facebook is a key channel for driving customer acquisition and incremental sales growth. Some of the very best now see Facebook as their most important DR channel with investments to back it up and StitcherAds, bringing to market the technology we refined onsite at Facebook’s campus, is making it easier for online retailers to grasp that opportunity before their competitors do.”
Facebook® is a registered trademark of Facebook Inc.
About StitcherAds
StitcherAds is the SaaS social performance ads platform specifically designed for online retailers to help them manage and optimize direct response ads on Facebook. The platform stitches together the retailer’s 1st party data with Facebook’s targeted reach at scale, enabling them to win 33% more customers in 67% less time.
StitcherAds is a Preferred Marketing Developer for Ads and has worked with savvy retailers including Lyle & Scott, SportPursuit, Tiffany Rose and Pets Pyjamas. Founded in 2009 as Betapond, the company’s investors include Investec Ventures Ireland, Delta Partners, Irrus Investments and Enterprise Ireland.
For more information
Contact:
Positive Marketing (for StitcherAds)
Paul Maher or Benedict
Sycamore, +44 20 3637 0640
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum